Changes in host cell molecules acquired by circulating HIV-1 in patients treated with highly active antiretroviral therapy and interleukin-2

AIDS. 2001 Jan 5;15(1):11-6. doi: 10.1097/00002030-200101050-00004.

Abstract

Objective: To analyse cell membrane proteins (CMP) acquired by HIV-1 present in the plasma of asymptomatic patients, and their modifications after a cycle of highly active antiretroviral therapy (HAART) and interleukin (IL)-2.

Design and methods: Plasma samples from eight drug-naive asymptomatic subjects underwent immobilized antibody capture (IAC) to detect CMP on the surface of circulating HIV-1. The CMP considered were lymphocyte subset markers (CD45RA, CD45RO), activation markers (HLA-DR), adhesion molecules (LFA-3), costimulatory proteins (B7-2), lymph-node homing receptors (CD62L) and pro-apoptosis molecules (FasL). This analysis was repeated after one cycle of HAART + IL-2, after virus rebound.

Results: LFA-3, followed by CD45RO and HLA-DR, are the most represented CMP on the surface of circulating virions in naive asymptomatic patients; CD45RA, CD62L, B7-2 and FasL are detected only occasionally. After rebound, a significant reduction of CD45RO and HLA-DR, but not of LFA-3, is observed on virions, whereas CD45RA and CD62L, as well as other molecules, are not affected, remaining almost undetectable.

Conclusions: Assuming that CMP on HIV-1 reflect the cellular origin of virions, activated T cells expressing CD45RO, HLA-DR, and LFA-3 may be the main source of HIV-1 in asymptomatic patients. After a cycle of HAART + IL-2, followed by therapy interruption, CD45RA and CD62L are detected on virions rarely, indicating that even during virus rebound, expanded naive T cells do not become a major target of virus replication. Furthermore, the presence of HLA-DR on rebound HIV-1 is decreased, consistent with decreased activation of the HIV-producing cells. More extensive investigation may clarify the significance of these findings with respect to pathogenesis.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Anti-HIV Agents / therapeutic use*
  • Antigens, CD / metabolism
  • Antiretroviral Therapy, Highly Active
  • B7-2 Antigen
  • CD4 Lymphocyte Count
  • CD58 Antigens / metabolism
  • Fas Ligand Protein
  • HIV Infections / drug therapy*
  • HIV Infections / immunology
  • HIV Infections / metabolism
  • HIV Infections / virology*
  • HIV Protease Inhibitors / therapeutic use
  • HIV-1 / metabolism*
  • HLA-DR Antigens / metabolism
  • Humans
  • Indinavir / therapeutic use
  • Interleukin-2 / therapeutic use*
  • L-Selectin / metabolism
  • Lamivudine / therapeutic use
  • Leukocyte Common Antigens / metabolism
  • Membrane Glycoproteins / metabolism
  • Membrane Proteins / metabolism*
  • Reverse Transcriptase Inhibitors / therapeutic use
  • Stavudine / therapeutic use
  • Viremia
  • Virion / metabolism

Substances

  • Anti-HIV Agents
  • Antigens, CD
  • B7-2 Antigen
  • CD58 Antigens
  • CD86 protein, human
  • FASLG protein, human
  • Fas Ligand Protein
  • HIV Protease Inhibitors
  • HLA-DR Antigens
  • Interleukin-2
  • Membrane Glycoproteins
  • Membrane Proteins
  • Reverse Transcriptase Inhibitors
  • L-Selectin
  • Lamivudine
  • Indinavir
  • Stavudine
  • Leukocyte Common Antigens